A U.S. group that reviews the value of medicines issued a critical report on Novartis’ Mayzent, calling the new multiple sclerosis drug’s $88,561 list price “far out of line” compared with the product’s benefits for patients.
Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.
EVERSANA unveiled Health Strategies Insights by EVERSANA, a comprehensive market access research and insights portfolio to help life science innovators make more informed decisions.
Walgreens Boots Alliance Inc. will pay $269.2 million to settle two whistleblower lawsuits accusing the pharmacy chain of civil fraud for overbilling federal healthcare programs for over a decade.
The cost of insulin for treating type 1 diabetes in the United States nearly doubled over a five-year period, underscoring a national outcry over rising drug prices, according to a new analysis shared with Reuters.
Johnson & Johnson raised U.S. prices on around two dozen prescription drugs, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among the company’s top-selling products.
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
Biogen Inc.’s Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG’s experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said.